XML 151 R57.htm IDEA: XBRL DOCUMENT
v3.20.4

Collaboration Agreements - Total Transaction Price to the Identified Performance Obligations (Details) - USD ($) $ in Thousands | Dec. 31, 2020 | Dec. 31, 2019
--- | --- | ---
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 87,225 |
Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 396,830 | $ 401,782
Combined 2018 AZ Agreement performance obligation | Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 293,223 |
Preclinical development service - IL-12 | Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 8,133 |
Preclinical development service - oncology development target | Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 8,133 |
Development and commercialization license and manufacturing obligation | Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | 85,750 |
Material right to receive development and commercialization rights | Combined 2018 AZ Agreements |  |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] |  |
Remaining performance obligations | $ 1,591 |

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mrna_Combined2018AZAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_Combined2018AZAgreementPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_IL12PerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_OncologyDevelopmentTargetPerformanceObligationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationLicenseAndManufacturingObligationsForIL12Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | mrna_PerformanceObligationAxis=mrna_DevelopmentAndCommercializationRightsAndManufacturingServicesForAnOncologyDevelopmentTargetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |